ACT-500

N/A

Report date: 2026/05/18 20:02:07
NME

Base Information

Drug NameACT-500
Drug Alias NameNM-6606ACT-500
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRetinoid X receptor alpha agonists
TargetsRetinoid X receptor alpha
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTenji (Xiamen) Biomedical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTenji (Xiamen) Biomedical Technology Co LtdNucMito (Hong Kong) Co LtdXiamen Amoytop Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A